Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...